RECENT Healthcare RESEARCH
In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.
Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system disorders.
Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.
On September 14, 2017, Abbott Laboratories (ABT) announced that its landmark clinical trial results show that the Amplatzer PFO Occluder device reduces the risk of ischemic stroke recurrence by 45.0%.
Baxter International (BAX) has been going through a cost transformation and reorganization process for some time. The initiative includes some leadership and management changes.
Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”
In August 2017, the FDA approved Teva Pharmaceutical’s (TEVA) Austedo for the treatment of adult individuals with tardive dyskinesia.
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
About 77.2% of analysts tracking BioMarin Pharmaceuticals in September 2017 suggested some form of a “buy” rating.
Baxter International (BAX) released its 2Q17 earnings results on July 26, beating the analysts’ estimates for both revenues and earnings per share.
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16.
In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.
Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”
With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
Edwards Lifesciences (EW) had tremendous growth in the first half of 2017. The stock has been recovering from the lows in late 2016 and has recently been on a bullish trend.
AstraZeneca’s (AZN) stock value has fallen ~11.9% over the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~16.6% over the next 12 months.
Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.
Royalties paid to Ligand Pharmaceuticals (LGND) based on the sales of Amgen’s (AMGN) Kyprolis are a major revenue driver for the company. In 2Q17, LGND earned royalties of ~$222 million on Kyprolis’ sales.